Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Common-Size Income Statement
Quarterly Data

Merck & Co. Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales -24.49 -23.24 -22.44 -26.74 -26.71 -26.76 -27.10 -28.06 -26.30 -28.89 -33.83 -28.64 -26.23 -27.22 -30.10 -44.21 -27.73 -29.06 -27.47 -30.92 -32.19 -28.92 -28.22
Gross profit 75.51% 76.76% 77.56% 73.26% 73.29% 73.24% 72.90% 71.94% 73.70% 71.11% 66.17% 71.36% 73.77% 72.78% 69.90% 55.79% 72.27% 70.94% 72.53% 69.08% 67.81% 71.08% 71.78%
Selling, general and administrative -16.40 -17.00 -15.74 -19.16 -15.78 -17.97 -17.11 -19.43 -16.85 -17.21 -14.61 -20.93 -17.76 -20.01 -20.58 -24.65 -19.52 -21.87 -21.19 -24.34 -20.88 -23.06 -22.42
Research and development -35.19 -21.72 -25.31 -65.80 -20.72 -88.60 -29.52 -27.30 -29.41 -19.17 -16.20 -22.68 -18.59 -37.90 -22.70 -46.64 -27.01 -19.53 -18.32 -21.47 -25.84 -18.61 -17.85
Restructuring costs -0.34 -0.50 -0.78 -1.74 -0.79 -1.00 -0.46 -0.35 -0.63 -0.97 -0.33 -1.29 -0.81 -0.72 -2.79 -2.47 -0.91 -0.76 -0.60 -1.63 -1.87 -0.50 -1.41
Operating income (loss) 23.58% 37.54% 35.73% -13.44% 36.00% -34.34% 25.81% 24.87% 26.82% 33.75% 35.02% 26.45% 36.61% 14.16% 23.83% -17.97% 24.83% 28.78% 32.42% 21.63% 19.21% 28.90% 30.09%
Other income (expense), net 0.97 -0.26 0.21 -0.54 -0.79 -1.14 -0.61 0.54 -2.87 -3.00 -4.45 2.46 3.42 0.90 4.28 2.04 2.49 3.59 -0.59 1.89 -0.28 -1.19 -1.74
Income (loss) from continuing operations before taxes 24.55% 37.28% 35.94% -13.98% 35.21% -35.48% 25.20% 25.40% 23.95% 30.75% 30.57% 28.91% 40.03% 15.06% 28.11% -15.93% 27.31% 32.37% 31.83% 23.52% 18.93% 27.71% 28.36%
Taxes on income from continuing operations -5.58 -3.38 -5.72 5.60 -5.45 -4.24 -5.69 -3.59 -2.21 -3.69 -3.48 -0.63 -5.28 -4.41 -2.24 -0.78 -3.85 -4.68 -5.13 -3.60 -3.55 -5.23 -1.90
Net income (loss) from continuing operations 18.98% 33.89% 30.22% -8.38% 29.76% -39.72% 19.50% 21.81% 21.75% 27.06% 27.09% 28.28% 34.75% 10.65% 25.87% -16.72% 23.46% 27.69% 26.70% 19.92% 15.38% 22.48% 26.46%
Income from discontinued operations, net of taxes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.46 0.00 2.91 4.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income (loss) 18.98% 33.89% 30.22% -8.38% 29.76% -39.72% 19.50% 21.81% 21.75% 27.06% 27.09% 27.82% 34.75% 13.56% 29.95% -16.72% 23.46% 27.69% 26.70% 19.92% 15.38% 22.48% 26.46%
Net (income) loss attributable to noncontrolling interests -0.02 -0.04 -0.03 0.00 -0.03 -0.02 -0.03 0.00 -0.03 -0.03 0.02 -0.03 -0.03 -0.01 -0.04 -0.02 -0.03 -0.07 0.00 -0.06 -0.05 0.22 0.49
Net income (loss) attributable to Merck & Co., Inc. 18.95% 33.86% 30.19% -8.38% 29.73% -39.74% 19.47% 21.81% 21.71% 27.03% 27.11% 27.79% 34.72% 13.55% 29.91% -16.74% 23.43% 27.61% 26.70% 19.86% 15.33% 22.70% 26.95%

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Merck & Co. Inc. operating income (loss) as a percentage of sales increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Income (loss) from continuing operations before taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Merck & Co. Inc. income (loss) from continuing operations before taxes as a percentage of sales increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Net income (loss) attributable to Merck & Co., Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Merck & Co. Inc. net income (loss) attributable to Merck & Co., Inc. as a percentage of sales increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.